Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Emyria Ltd

EMD.AX ✓ COMPLIANT ☆ Track — members

ASX · Healthcare · Biotechnology & Medical Research ·

Australia Micro Cap Analyst: N/A

Last Close

$0.03

▲ +2.17%

Market Cap $26.74M · Vol 233.25K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$26.74M

Micro Cap

Div Yield

0.00%

Annual dividend

EPS Growth

N/A

YoY

RSI (14)

47.06

Momentum

Beta

1.04

vs Market

52W High

$0.06

34.71% below

52W Low

$0.03

33.07% above

Volume

233.25K

Avg 1.08M

P/B

3.23

Price-to-book

ROE

N/A

Return on equity

Free Float

74.17%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Emyria Ltd (EMD.AX) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does EMD.AX pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+0.00%

+20.51%

+17.50%

-12.96%

YTD

-20.34%

+4.44%

-44.73%

-75.72%

Financials & Valuation

TTM · Annual

Total Revenue	$917.74K
Net Income	$-2,067,932.00
Revenue Growth (YoY)	+136.17%
Gross Margin	-17.36%
Operating Margin	-213.09%
Net Profit Margin	-225.33%
ROE	N/A
ROA · ROIC	-52.19% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	9.01
P/B	3.23
P/FCF	N/A
EPS Growth	N/A
Outstanding Shares	806.56M

Technical Indicators

50-Day SMA	$0.03
200-Day SMA	$0.04
RSI (14)	47.06
Beta	1.04
52-Week High	$0.06
52-Week Low	$0.03

Volume Today	233.25K
Avg Daily Volume (30D)	1.08M
Relative Volume	0.22x
Volatility (10D)	57.85
Volatility (30D)	66.74
Free Float	74.17%

Analyst Consensus

N/A

Current Price $0.03

Mean Target N/A

52W Low$0.03 52W High$0.06

Current

Target

$0.03 $0.06

Current Analyst target

· 0 analysts

Identifiers

ExchangeASX

FIGIBBG00R41CRB8

ISINAU0000073645

CountryAustralia

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateN/A

TypeStocks

Instrument TypeFULLPAID Fully Paid Ordinary

Similar Halal Stocks

LONN.S Lonza Group AG -1.78% RVMD Revolution Medicines Inc +0.85% ONC BeOne Medicines AG -2.40% 068270.KS Celltrion Inc -0.50% ABVX Abivax SA -2.05%

Company Profile

Emyria Limited is an Australia-based early-stage drug development company. The Company is focused on delivering and developing treatments for mental health and select neurological conditions, guided by real-world data collected with patients across its wholly owned clinical service subsidiaries. Its pipeline comprises MDMA analogue drug development and commercialization of novel serotonin-releasing agents. Its Emyria Healthcare provides evidence-based treatment for patients not finding relief from conventional care, while also helping evaluate emerging new therapies like assisted therapy for post-traumatic stress disorder (PTSD) and assisted therapy for treatment-resistant depression. Its Emyria Data is a robust and ethically sourced real-world data gathered with patients and used to improve its therapy and drug development programs. Its Emyria’s Pipeline includes new psychedelic-assisted therapies and drug treatments for mental health and select neurological diseases.